MORPHOLOGICAL AND STRUCTURAL CHANGES IN MYOCARDIUM, LIPID AND CARBOHYDRATE METABOLISM DURING DIFFERENT OUTCOMES OF CHRONIC HEART FAILURE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND DIABETES MELLITUS TYPE II
Diabetes mellitus (DM) type II is an independent risk factor for cardiovascular system injury. To avoid progression of ischemic heart failure (IHF) it is important to find early signs of myocardial injury also as carbohydrate and lipid metabolism alterations.
The objective of the study: to establish features of structural and functional changes in myocardium, carbohydrate and lipid metabolism, in patients with different outcomes of chronic heart failure (CHF), caused by IHD and DM type II.
Material and methods. Examination of 100 patients who have CHF with IHF and DM type II was performed. Patients were divided in two groups, according to outcome: group I (n=66) – patients with favorable outcome, mean age 60.0 [55.8; 63.3] years, group II (n=34) – unfavorable outcome of CHF, mean age 58.0 [55.0; 60.3] years.
We analysed complaints, cardiologycal anamnesis, cardiovascular risk factors, and physical examination data. Transthoracic echocardiography (TTE), carbohydrate and lipid panel were assessed to find out early specific signs of myocardial injury.
Results. We find out statistically significant associations between TTE results, lipid panel and CHF progression in study population.
Conclusions. Comparative analysis showed that degree of CHF in patients with IHD and DM type II that have preserved LV EF is associated with: duration of DM and CHF, arterial hypertension (AH) level and degree of carbohydrate and lipid metabolism disturbances. Early TTE signs of unfavorable outcome are: increase of transmitral deceleration time (Dt), increase of mean PA pressure (PA MP) even in range lower the 20 mmHg.
Severino, P., D’Amato, A., Netti, L., Pucci, M., De Marchis, M., Palmirotta, R. et. al. (2018). Diabetes Mellitus and Ischemic Heart Disease: The Role of Ion Channels. International Journal of Molecular Sciences, 19 (3), 802. doi: https://doi.org/10.3390/ijms19030802
IDF Diabetes Atlas (2015). Available at: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html
Kumar, R., Kerins, D. M., Walther, T. (2015). Cardiovascular safety of anti-diabetic drugs. European Heart Journal – Cardiovascular Pharmacotherapy, 2 (1), 32–43. doi: http://doi.org/10.1093/ehjcvp/pvv035
Stratton, I. M., Adler, A. I., Neil, H. A. et. al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321 (7258), 405–412. doi: http://doi.org/10.1136/bmj.321.7258.405
Chatterjee, S., Khunti, K., Davies, M. J. (2017). Type 2 diabetes. The Lancet, 389 (10085), 2239–2251. doi: http://doi.org/10.1016/s0140-6736(17)30058-2
Bowes, C. D., Lien, L. F., Butler, J. (2019). Clinical aspects of heart failure in individuals with diabetes. Diabetologia, 62 (9), 1529–1538. doi: http://doi.org/10.1007/s00125-019-4958-2
Jia, G., Whaley-Connell, A., Sowers, J. R. (2017). Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia, 61 (1), 21–28. doi: http://doi.org/10.1007/s00125-017-4390-4
Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., Virmani, R. (2017). Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 37 (2), 191–204. doi: http://doi.org/10.1161/atvbaha.116.306256
Saotome, M., Ikoma, T., Hasan, P., Maekawa, Y. (2019). Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics. International Journal of Molecular Sciences, 20 (14), 3552. doi: http://doi.org/10.3390/ijms20143552
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S. et. al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37 (27), 2129–2200. doi: http://doi.org/10.1093/eurheartj/ehw128
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S. et. al. (2016). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). European Heart Journal, 37 (27), 2129–2200. doi: http://doi.org/10.1093/eurheartj/ehw128 American diabetes association. Standards of Medical Care in Diabetes–2017 (2017). Diabetes Care, 40 (1), 135.
Klimov, A. N. (1977). Prichiny i usloviya razvitiya ateroskleroza. Preventivnaya kardiologiya, 260–321.
Celermajer, D. S., Sorensen, K. E., Gooch, V. M., Spiegelhalter, D. J., Miller, O. I., Sullivan, I. D. et. al. (1992). Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. The Lancet, 340 (8828), 1111–1115. doi: http://doi.org/10.1016/0140-6736(92)93147-f
Ivanova, O. V., Rogoza, T. V., Balakhonova, G. N. (1998). Opredelenie chuvstvitelnosti plechevoi arterii k napriazheniiu sdviga na endotelii kak metod ocenki sostoianiia endoteliizavisimoi vazodilatacii s pomoschiu ultrazvuka vysokogo razresheniia u bolnykh s arterialnoi gipertoniei. Kardiologiia, 3, 37–41.
Savarese, G., Lund, L. H. (2017). Global Public Health Burden of Heart Failure. Cardiac Failure Review, 3 (1), 7–11. doi: http://doi.org/10.15420/cfr.2016:25:2
Braunwald, E. (2015). The war against heart failure: the Lancet lecture. The Lancet, 385 (9970), 812–824. doi: http://doi.org/10.1016/s0140-6736(14)61889-4
Cleland, J. G. F., Bunting, K. V., Flather, M. D., Altman, D. G., Holmes, J. et. al. (2017). Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39 (1), 26–35. doi: http://doi.org/10.1093/eurheartj/ehx564
Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., Scirica, B. M. (2015). Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology, 3 (5), 356–366. doi: http://doi.org/10.1016/s2213-8587(15)00044-3
Lam, C. S. (2015). Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. Diabetes and Vascular Disease Research, 12 (4), 234–238. doi: http://doi.org/10.1177/1479164115579006
Lehrke, M., Marx, N. (2017). Diabetes Mellitus and Heart Failure. The American Journal of Medicine, 130 (6), S40–S50. doi: http://doi.org/10.1016/j.amjmed.2017.04.010
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V. et. al. (2019). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 41 (2), 255–323. doi: http://doi.org/10.1093/eurheartj/ehz486
Copyright (c) 2020 Ekaterina Lipakova, Oleksandr Bilchenko, Olena Vysotska, Liubov Rysovana
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.